Mr. Andre Larente reports

DIAGNOS ANNOUNCES CLOSING OF PRIVATE PLACEMENT

Diagnos Inc. has closed a non-brokered private placement of 6,715,370 units issued at a price of 30 cents per unit for gross proceeds of $2,014,611.

Each unit consists of one common share and one common share warrant.

As part of the closing of the private placement, 6,715,370 warrants have been issued to the subscribers. Each warrant can be exercised to purchase one share at a price of 40 cents per share for a period of 18 months ending Aug. 5, 2026.

In connection with the closing of the private placement, the corporation: (i) paid cash commissions totalling $39,246.72; and (ii) issued an aggregate number of 130,821 finders' warrants to five qualified firms acting at arm's length to the corporation. Each finder's warrant entitles the holder to purchase one share at an exercise price of 40 cents per share for a period of 18 months ending Aug. 5, 2026.

The net proceeds from the private placement will be used to finance product development and commercialization of AI-based screening services, regulatory affairs, as well as general and administrative operations.

All securities issued as part of the private placement are subject to a statutory hold period ending June 6, 2025.

The closing of the private placement remains subject to receipt of all required approvals, including the approval of the TSX Venture Exchange, as well as execution of formal documentation.

About Diagnos Inc.

Diagnos is a publicly traded Canadian corporation dedicated to early detection of critical health problems based on its Flaire artificial intelligence (AI) platform. Flaire allows for quick modifying and developing of applications such as CARA (computer-assisted retina analysis). CARA's image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a cost-effective tool for real-time screening of large volumes of patients.

We seek Safe Harbor.